Vertex Pharmaceuticals | VRTX

Stock Price
439.65
Daily Change
-6.04 -1.36%
Monthly
10.07%
Yearly
29.32%
Q2 Forecast
433.25
Peers Price Chg Day Year Date
AbbVie 162.79 -1.70 -1.03% 12.35% May/21
Acadia Pharmaceuticals 15.19 0.09 0.60% -38.75% May/21
Agios Pharmaceuticals 34.06 0.87 2.62% 27.61% May/21
Alnylam Pharmaceuticals 148.59 -1.65 -1.10% -23.03% May/21
Amgen 313.66 -0.75 -0.24% 40.03% May/21
Arrowhead Research 24.85 0.03 0.12% -31.96% May/21
Biogen 226.98 -4.60 -1.99% -26.03% May/21
BioMarin Pharmaceutical 76.53 -0.52 -0.67% -17.51% May/21
Bristol-Myers Squibb 42.44 -0.87 -2.01% -35.51% May/21
Gilead Sciences 67.29 -0.57 -0.84% -14.41% May/21
Incyte 57.23 0.07 0.12% -11.12% May/21
Insmed 24.64 -0.90 -3.52% 21.32% May/21
Ionis Pharmaceuticals 37.76 -0.96 -2.48% -7.25% May/21
J&J 150.82 -0.65 -0.43% -3.86% May/21
Merck 130.58 -0.31 -0.24% 14.05% May/21
Moderna 141.85 0.95 0.67% 11.92% May/21
Neurocrine Biosciences 141.08 -0.57 -0.40% 50.89% May/21
Novartis 93.89 0.52 0.56% 2.90% May/21
Pfizer 28.53 0.04 0.14% -26.37% May/21
PTC Therapeutics 38.95 -1.17 -2.92% -34.09% May/21
Ultragenyx Pharmaceutical 40.42 -1.11 -2.67% -20.29% May/21
Regeneron Pharmaceuticals 992.94 6.66 0.68% 32.13% May/21
Roche Holding 234.40 -2.70 -1.14% -18.16% May/21
Sanofi 90.00 0.84 0.94% -10.27% May/21
Sarepta Therapeutics 127.94 -2.89 -2.21% -14.17% May/21
United Therapeutics 276.40 1.73 0.63% 26.45% May/21
Vertex Pharmaceuticals 439.65 -6.04 -1.36% 29.32% May/21

Indexes Price Day Year Date
US500 5315 7.34 0.14% 26.78% May/21
USND 16806 11.28 0.07% 32.12% May/21
US400 3008 -11.41 -0.38% 21.86% May/21
US100 18698 24.03 0.13% 35.01% May/21

Vertex Pharmaceuticals traded at $439.34 this Tuesday May 21st, decreasing $6.35 or 1.42 percent since the previous trading session. Looking back, over the last four weeks, Vertex Pharmaceuticals lost 9.99 percent. Over the last 12 months, its price rose by 29.23 percent. Looking ahead, we forecast Vertex Pharmaceuticals to be priced at 433.25 by the end of this quarter and at 420.76 in one year, according to Trading Economics global macro models projections and analysts expectations.

Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface. It offers pipeline of small molecule medicines in other serious diseases where it has insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.